Safety and Outcomes in Multiplane Facial Rejuvenation with Tranexamic Acid: A Cohort Study.

Background: Tranexamic acid (TXA) has demonstrated promising outcomes in plastic surgery. Our aim was to assess the effect of TXA in intraoperative bleeding, operative time, and complications among patients undergoing facial surgical procedures. Methods: A retrospective cohort study of patients who underwent multiplane facial rhytidectomy from January 2018 to September 2022 at the Clinica Ziegler, Lima, Peru. Patients were divided into two groups according to the use of intravenous plus local infiltration of TXA. We performed the chi square test to assess associations among categorical variables, the Student t test and Mann-Whitney U test for categorical with continuous variables, and Pearson correlation for quantitative variables. Results: A total of 100 patients were included with 50 patients in each group. The median age was 59.5 years and the majority were women (88%). The median operative time was 288.5 minutes. The TXA group presented less intraoperative bleeding (40 versus 90 mL, P < 0.05) and shorter operative time (237 versus 353 minutes, P < 0.05); no differences in the development of hematoma (2% versus 12%, P = 0.11), less ecchymosis (2% versus 36%, P < 0.05), edema (2% versus 100%, P < 0.05), and time to drain removal (3 versus 6 days, P < 0.05). Conclusions: TXA improves the short- and long-term outcomes of patients who undergo multiplane facial rhytidectomy. It also decreases intraoperative bleeding by more than half and reduces the operative time by one third. Moreover, patients receiving TXA presented significantly less ecchymosis, edema, and time to drain removal.

Prepectoral and Retropectoral Breast-implant-Associated Anaplastic Large-cell Lymphoma.

Breast-implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a non-Hodgkin lymphoma that arises in the space between the surface of a breast implant and the fibrous capsule that grows around the implant. Since its first description 20 years ago, almost 1000 cases of BIA-ALCL have been diagnosed worldwide. Nowadays, guidelines describe the diagnosis, staging, and treatment of this disease. We present the first two cases diagnosed and treated in Peru, demonstrating a wide range of aggressiveness of BIA-ALCL.

Descripción de un caso de adenomatosis erosiva del pezón: tratamiento quirúrgico / Case report of erosive adenomatosis of the nipple: Surgical treatment

La adenomatosis erosiva es una neoplasia benigna poco frecuente que afecta al pezón. Caracterizado por erosión, telorrea, telorragia, nodularidad, prurito y eritema, ocasionando un proceso destructivo progresivo del pezón, el cual puede ser confundido con la enfermedad de Paget; motivo por el cual el conocimiento de esta enfermedad es fundamental para evitar el sobretratamiento quirúrgico. Presentamos el caso de una paciente de 35 años diagnosticada y tratada con cirugía, así como la revisión de la literatura de esta entidad. (AU)

Erosive adenomatosis is a rare benign neoplasm that affects the nipple. Characterized by erosion, telorrhoea, telorrhagia, nodularity, pruritus and erythema, causing a progressive destructive process of the nipple, which can be confused with Paget's disease; which is why knowledge of this pathology is essential to avoid surgical overtreatment. We present the case of a 35-year-old patient diagnosed and treated with surgery, as well as a review of the literature on this entity. (AU)

Tumor phyllodes: reporte de un caso tratado con cirugía oncoplástica extrema y revisión de la literatura / Phyllodes tumor: Case report treated with extreme oncoplastic surgery and literature review

El tumor phyllodes representa el 1% de los tumores primarios de la mama, es una rara neoplasia fibroepitelial que tiene a la cirugía como piedra angular en el tratamiento: la resección con márgenes amplios (mayores o iguales a 1 cm) y la mastectomía son los tratamientos recomendados. Tomando en cuenta el impacto de los bordes quirúrgicos en la recurrencia local, el gran volumen de resección, la velocidad de crecimiento y la dificultad de predecir el comportamiento tumoral con el estudio preoperatorio de biopsia percutánea; la cirugía de conservación es un reto en muchos casos. Presentamos el caso de una paciente tratada con cirugía oncoplástica extrema, así como la revisión de la literatura de esta entidad. (AU)

The phyllodes tumor represents 1% of the primary tumors of the breast, it is a rare fibroepithelial neoplasia that has surgery as a cornerstone in the treatment: resection with wide margins (greater than or equal to 1 cm) and mastectomy are the recommended treatments; considering the impact of the surgical edges on local recurrence, the large resection volume, growth speed and the difficulty of predicting tumor behavior with the pre-operative percutaneous biopsy study; Conservation surgery is challenging in numerous instances. We present the case of a patient treated with extreme oncoplastic surgery, as well as a review of the literature on this entity. (AU)

Double heterozygous mutation in RAD50 and ATM genes in a Peruvian family with five cancer types: a case report.

INTRODUCTION: Cancer is the second leading cause of death worldwide, with 70% of cancer deaths occurring in low- or middle- income countries. To mitigate the mortality of this disease, it is recommended the evaluation of multiple high-penetrance genes. METHODS: We used a multi-gene panel testing to identify germline variants in a unique case of a breast cancer patient with a family history of five different neoplasm types. The patient, at the age of 50 years, was diagnosed with a high-grade cribriform ductal carcinoma in situ in her left breast. RESULTS: We identified two heterozygous mutations, one classified as pathogenic/likely pathogenic in RAD50 and the other classified as a variant of uncertain significance (VUS) in ATM. CONCLUSION: In conclusion, the use of the multi-gene panel leads to the identification of a double heterozygous mutation in RAD50 and ATM in a breast cancer patient from a Peruvian family with several cancer types. This data helps our physician team and the patient to choose a treatment following the post-test genetic counseling.